• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration

    2/28/25 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACHL alert in real time by email

    LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange Act). As previously reported, the Company has called a General Meeting for March 20, 2025 to obtain shareholder approval to commence a members' voluntary liquidation. The planned delisting of the ADSs is being undertaken in connection with the contemplated liquidation.

    The Company intends to file a Form 25 (Notification of Removal from Listing) with the SEC on March 10, 2025, and expects the last trading day of the Company's common stock on Nasdaq will be March 20, 2025. Following delisting from Nasdaq, any trading in the Company's ADSs would occur only in privately negotiated sales and potentially on an over-the-counter market if a broker makes a market in the ADSs. There is no guarantee, however, that a broker will make such a market or that trading of the ADSs will continue on an over-the-counter market or otherwise.

    The Company also intends to file a Form 15 (Certification and Notice of Termination From Registration) with the SEC on or about March 20, 2025. Upon filing, the Company's obligation to file periodic reports with the SEC, including Forms 20-F and 6-K, will be suspended immediately and will terminate when deregistration becomes effective 90 days after the Form 15 is filed.

    Forward Looking Statements

    This press release contains express or implied forward-looking statements that are based on the Company management's belief and assumptions and on information currently available to the Company's management. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company's intention to delist from Nasdaq and to deregister from the SEC. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual actions to be materially different from any future actions expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent the Company's views as of the date of this press release. While the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release.

    For further information, please contact:

    Meru Advisors

    Lee M. Stern

    [email protected]



    Primary Logo

    Get the next $ACHL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHL

    DatePrice TargetRatingAnalyst
    4/5/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ACHL
    SEC Filings

    View All

    SEC Form 15-12G filed by Achilles Therapeutics plc

    15-12G - Achilles Therapeutics plc (0001830749) (Filer)

    3/21/25 9:41:03 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Achilles Therapeutics plc

    6-K - Achilles Therapeutics plc (0001830749) (Filer)

    3/20/25 5:30:00 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Achilles Therapeutics plc

    S-8 POS - Achilles Therapeutics plc (0001830749) (Filer)

    3/19/25 4:16:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration

    LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange Act). As previously reported, the Company has called a General Meeting for March 20, 2025 to obtain shareholder approval to commence a members' voluntary liquidation. The planned delisting of the ADSs is being undertaken in connection with the contemplated liquidation. Th

    2/28/25 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

    - Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (NASDAQ:AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data

    12/24/24 9:30:00 AM ET
    $ACHL
    $AZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

    LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. The transfer of the Company's listing to the Nasdaq Capital Market is not expected to have any impact on trading in the Company's ADSs. The Company's ADSs will continue to trade under the symbol "ACHL." The approval by Nasdaq w

    11/19/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Achilles Therapeutics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Achilles Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $8.00 previously

    4/5/24 7:22:16 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Achilles Therapeutics plc

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    11/14/24 4:23:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Achilles Therapeutics plc

    SC 13G - Achilles Therapeutics plc (0001830749) (Subject)

    9/25/24 7:14:31 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Achilles Therapeutics plc (Amendment)

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    3/29/24 4:30:59 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Leadership Updates

    Live Leadership Updates

    View All

    Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

    LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022. James brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies. Most recently, he was Chief Business Officer at Sosei Heptares, where he completed a major collaboration with Neurocrine Biosciences for a Phase II-ready M4 agonist for schizophrenia, and led deals

    6/30/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

    LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director. Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities. Bernhard is a veteran biotechnology and pharmaceutical executive with more than three decades in senior leadership roles. He most recently served as CEO of Biotest AG in Germany and also served as chairman of the board of directors at Symphogen A/S, Denmark until its acquisition by Servier SA in June 2

    5/4/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

    LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB). "We are very pleased to welcome leading experts Dr. Gros and Dr. Creelan to our Scientific Advisory Board. With two ongoing clinical trials, CHIRON in non-small cell lung cancer (NSCLC) and THETIS in melanoma, their extensive research experience and deep clinical expertise with cell-based immunotherapies for the treatment of solid tumors will be invaluable as we continue to advance the clinic

    2/7/22 7:30:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Financials

    Live finance-specific insights

    View All

    Achilles Therapeutics Reports Third Quarter 2024 Financial Results

    – Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –         LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has engaged BofA Securities as a financial advisor in the process of exploring strategic options.Achilles Chief Scientific Officer, Sergio Quezada, presented "Targeting Clonal Neoantigens with Pre

    11/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

    – Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t

    8/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    – Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. "Just after the close of the first quarter, we shared the interim Phase I/

    5/8/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care